Alterations in phosphorylation of cellular proteins are a hallmark of malignant transformation. Degradation of these phosphoproteins could generate cancer-specific class I MHC-associated phosphopeptides recognizable by CD8 ؉ T lymphocytes. In a comparative analysis of phosphopeptides presented on the surface of melanoma, ovarian carcinoma, and B lymphoblastoid cells, we find 5 of 36 that are restricted to the solid tumors and common to both cancers. Differential presentation of these peptides can result from differential phosphorylation of the source proteins. Recognition of the peptides on cancer cells by phosphopeptide-specific CD8 ؉ T lymphocytes validates the potential of these phosphopeptides as immunotherapeutic targets.
Alterations in phosphorylation of cellular proteins are a hallmark of malignant transformation. Degradation of these phosphoproteins could generate cancer-specific class I MHC-associated phosphopeptides recognizable by CD8 ؉ T lymphocytes. In a comparative analysis of phosphopeptides presented on the surface of melanoma, ovarian carcinoma, and B lymphoblastoid cells, we find 5 of 36 that are restricted to the solid tumors and common to both cancers. Differential presentation of these peptides can result from differential phosphorylation of the source proteins. Recognition of the peptides on cancer cells by phosphopeptide-specific CD8 ؉ T lymphocytes validates the potential of these phosphopeptides as immunotherapeutic targets.
tandem mass spectrometry ͉ immobilized metal-affinity chromatography C lass I MHC molecules are cell surface proteins that bind and display a broad repertoire of peptides produced by degradation of cellular proteins to CD8 ϩ T lymphocytes. Changes in protein expression and͞or metabolism that accompany infection or cellular transformation alter the peptides that are displayed by these MHC molecules. CD8 T lymphocyte recognition of specific peptides on pathogen infected or cancerous cells leads to activation of cytolysis and cytokine secretion programs, resulting in inflammation and cellular destruction. Proteins degraded by the proteasome are a major source of peptides displayed on class I MHC molecules (1) . Rapid protein degradation by the proteasome also is an important mechanism for regulating the activity of many transcription factors, cell growth modulators, signal transducers, and cell cycle proteins (2) (3) (4) . Interestingly, this degradation often depends on E3 ubiquitin-ligases whose activity in turn depends on phosphorylation of the target protein (5) (6) (7) . Malignant transformation leads to alterations in the protein kinase pathways regulating cell growth, differentiation, and cell death (8, 9) . Deregulated signaling cascades often lead to increases in the extent of protein phosphorylation within the cell (10) . We hypothesized that degradation of these proteins would generate phosphopeptides that are uniquely or differentially presented on malignant cells by class I MHC molecules. These phosphopeptides would be attractive candidates for cancer immunotherapy.
Results and Discussion
To define class I MHC-associated phosphopeptides derived from proteins potentially associated with malignant transformation, we analyzed mixtures of Ͼ10,000 peptides presented by HLA-A*0201 molecules on the surface of two melanoma cells, DM331 and SLM2, an ovarian carcinoma, COV413, and an Epstein-Barr virus-transformed B lymphoblastoid cell line (BLCL), JY. Peptides associated with immunoaffinity-purified HLA-A*0201 molecules were extracted with acid (11) and converted to methyl esters under acidic conditions with either d 0 -or d 3 -methanol (12) . Samples with different isotopic labels from any two of the above cell lines were combined, enriched for phosphopeptides by immobilized metal-affinity chromatography and analyzed by the combination of nanoflow-HPLC and tandem MS on a hybrid linear-quadrupole ion-trap͞Fourier-transform mass spectrometer (11, 13) . In these experiments, signals for class I MHC phosphopeptides presented on the surface of both cell lines appear in the mass spectrum as doublets separated by 3 m͞z units per carboxylate group in the molecule. Phosphopeptides that are unique to one or the other cell line appear as singlets. Reproducibility of the peptide extraction, derivatization, and analytical methodology was demonstrated by analyzing multiple d 0 -and d 3 -labeled samples prepared from the same or different lysates of JY BLCL. Identical doublet peaks were observed in each experiment (data not shown). Next, we analyzed samples prepared by mixing d 0 -and d 3 -labeled peptide methyl esters from multiple pairs of the above four cell lines. We detected and sequenced 36 phosphopeptides presented by HLA-A*0201 on one or more of the four cell lines (Table 1) . Although relatively small in comparison to the number identified in cell extracts (14) , the number of phosphopeptides detected is likely to be limited by the HLA-A*0201-binding motif (15) and the location of the phosphorylated residue (11) . The observed peptides match to 35 source proteins in the human protein database (www.ncbi.nlm.nih.gov͞BLAST).
Because it has been suggested that the main source of peptides presented by class I MHC molecules involves proteasomal degradation of defective ribosomal products or misfolded proteins (16), we examined the peptides for evidence that the observed phosphorylation sites result from normal protein phosphorylation processes. Of the 35 identified source proteins, 28 have described functions (Table 3 , which is published as supporting information on the PNAS web site). Twenty-one of the identified source proteins are known phosphoproteins (Table 1) ; five others are members of known phosphoprotein families, but their phosphorylation status is presently undocumented. Of the seven source proteins with unknown functions, one (FLJ13725) has been shown to be phosphorylated (14) . Of the 36 phosphorylation sites shown in Table 1 , seven have been reported previously (14, (17) (18) (19) (20) . Presentation of the peptide, YLDpSGIHSGA (residues 30-39 of ␤-catenin) is particularly noteworthy. Phos-phorylation of Ser 33 is necessary for targeting ␤-catenin for ubiquitination and proteasome-mediated degradation (17, 21) , and the proteasome is intimately involved in the creation of most class I MHC-associated epitopes. These observations suggest a link between this particular phosphorylation and the process of source protein degradation that leads to display of the phosphopeptide by HLA-A*0201. These results suggest that the observed class I MHC-associated phosphopeptides are derived from degradation of properly folded, biologically active proteins that are recognized and posttranslationally modified by their respective kinases.
Next, we evaluated whether a correlation exists between the phosphopeptides presented on each of the four cell lines and the annotated functions of the corresponding source proteins. Twenty phosphopeptides presented by HLA-A*0201 are detected on at least one cancer cell and on JY BLCL ( Table 1) . Fifteen of these phosphopeptides are derived from source proteins with known functions (Table 3) . Seven phosphopeptides are involved in cell cycle regulation and represent all source proteins with this function that we identified. A likely explanation of this finding is that both JY BLCL and the cancer cells are actively proliferating, although JY BLCL is virally transformed and not derived from a tumor. Because cancer cells are more likely to be in cycle than untransformed cells, we believe that phosphopeptides in this category still have potential as immunotherapeutic targets. 
Protein sources were obtained by searching peptide sequences against the nr and refseq databases for human proteins (www. ncbi.nlm.nih.gov͞BLAST). Bolded text indicates known phosphoproteins. Italicized text indicates that the protein is a member of a known phosphoprotein family but that phosphorylation status is undocumented. Underlined residues indicate known phosphosites (www.phosphosite.org). Ϫ, not detected; ϩ, 0.5-5 copies per cell; ϩϩ, 5-50 copies per cell; ϩϩϩ, 50 -500 copies per cell; ϩϩϩϩ, Ͼ500 copies per cell. † Met and Met ox forms of the peptide were detected. ‡ The Cys residue is either oxidized or cysteinylated. § The Met ox form of the peptide was detected. ¶ C-terminal truncated versions of the peptide were found on several of the cell lines. ʈ The peptide modified with ϩ18 mass units on the second S was also identified on DM331 and COV413. † † The 10-mer (RQApSIELPSM) was found on JY BLCL.
Of the 36 phosphopeptides detected in association with HLA-A*0201, 11 are presented on one or more cancer cell lines, but not on JY BLCL (Table 1) . Five of these peptides are of particular interest as immunotherapeutic targets because they are found on all three cancer cell lines. Source proteins for 10 of 11 phosphopeptides in this category have known functions (Table 3) . Several of these proteins (IRS2, Tensin-3͞TEM6, BCAR3, and ␤-catenin) are involved in cytoplasmic signaling. This group, as well as the transcriptional activator Jun-C͞D, are known to either be up-regulated or more active in some cancer cells (22) (23) (24) (25) (26) (27) (28) (29) . Thus, the phosphopeptides displayed on cancer cells and not JY BLCL are preferentially derived from source proteins associated with cytoplasmic signaling pathways and cellular transformation.
To understand the basis for differential display of phosphopeptides by HLA-A*0201 molecules on JY BLCL and the three cancer cell lines, Western blot analysis of cell lysates was used to determine the levels of the source proteins, IRS2 and ␤-catenin, and the corresponding phosphosites observed in the MHC-associated phosphopeptides. All four cell lines express IRS2 and ␤-catenin proteins (Fig. 1) . However, we detected only IRS2 phosphorylated on Ser 1100 and ␤-catenin phosphorylated on Ser 33 in the three cancer cell lines (Fig. 1) . Because the phosphopeptides RVApSPTSGV (residues 1097-1105 of IRS2) and YLDpSGIHSGA (residues 30 -39 of ␤-catenin) are presented by HLA-A*0201 on the three cancer cell lines but not on JY BLCL (Table 1) , we conclude that the differential presentation of these epitopes is due to differential phosphorylation of the corresponding source proteins. Interestingly, we have not been able to detect the nonphosphorylated form of the IRS2 epitope in the extracted peptides by MS (data not shown), indicating that it is either absent or present at levels at least 5-fold lower than that of the corresponding phosphopeptide. The nonphosphorylated IRS2 peptide does bind to purified HLA-A*0201 in vitro, but its affinity is lower by a factor of four relative to that of the phosphorylated form (Table 4 , which is published as supporting information on the PNAS web site). Phosphorylation-augmented binding also was observed for TRAPPC1 129 -137 and CDC25b 38 -46 to a lesser extent, whereas phosphorylation diminished the binding of ␤-catenin 30 -39 . However, all of the measured affinities are within the range observed for other naturally processed peptides known to be displayed. Thus, phosphorylation of Ser 1100 in pIRS2 1097-1105 might promote display of this epitope by enhancing its binding to HLA-A*0201. Alternatively, phosphorylation may augment degradation and processing of the parent protein or prevent enzymatic cleavage of the peptide in the proteasome.
To demonstrate the potential of using class I MHC-restricted phosphopeptides as potential therapeutics against cancer, we generated CD8 ϩ T lymphocytes that recognize the phosphopeptides presented by HLA-A*0201 from the source proteins, IRS2, ␤-catenin, and CDC25b. Mice expressing a transgenic recombinant HLA-A*0201 molecule (AAD) were immunized with activated bone-marrow-derived dendritic cells pulsed with either phosphorylated IRS2 (pIRS2 1097-1105 ), phosphorylated ␤-catenin (p␤-catenin [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] ), or phosphorylated CDC25b (pCDC25b 38-46 ) peptides. Three weeks later, CD8 ϩ T lymphocytes were isolated and cultured in vitro in the presence of irradiated splenocytes pulsed with the same phosphopeptides (11). These CD8 ϩ T lymphocytes secrete IFN-␥ when they specifically recognize target cells that have been pulsed with synthetic peptides corresponding to the phosphorylated forms of these epitopes but not the nonphosphorylated homologues ( Fig. 2A) . We conclude that MHC phosphopeptides can be used to elicit CD8 ϩ T lymphocytes that recognize only the phosphorylated form of the peptides. Next, we evaluated whether these specific CD8 ϩ T lymphocytes would recognize phosphopeptides generated from intracellular source proteins by the endogenous class I MHC antigen-processing pathway. CD8 ϩ T lymphocytes specific for pIRS2 [1097] [1098] [1099] [1100] [1101] [1102] [1103] [1104] [1105] or p␤-catenin 30 -39 recognize all three cancer cell lines but not JY BLCL (Fig. 2B) , consistent with their representation as determined by MS (Table 1) . CD8 ϩ T lymphocytes specific for pCDC25b 38 -46 recognize the three cancer cells and JY BLCL but with different efficiencies (Fig.  2B) . Levels of IFN-␥ secreted by CD8 ϩ T lymphocytes that recognize the COV413 ovarian carcinoma and DM331 melanoma are approximately 10-fold higher then that released upon recognition of SLM2 melanoma and JY BLCL. These results are consistent with the levels of epitope detected in association with the HLA-A*0201 molecule by MS (Table 1) .
To definitively show that phosphopeptide display and T cell recognition were due to expression and phosphorylation of the expected source protein, we transiently transfected the murine colorectal adenocarcinoma MC38AAD with a plasmid encoding human IRS2 (phIRS2-GFP) and evaluated its recognition by pIRS2 1097-1105 -specific CD8 ϩ T lymphocytes. Although we detected a low level of murine IRS2 in untransfected or mocktransfected cells by Western blot, MC38AAD cells transfected with the hIRS2-GFP plasmid showed a high level of human IRS2 that was also phosphorylated on Ser 1100 (data not shown). pIRS2 1097-1105 -specific CD8 ϩ T lymphocytes only produced IFN-␥ in response to MC38AAD cells that were transiently transfected with phIRS2-GFP or were exogenously pulsed with the RVApSPTSGV peptide and did not respond to MC38AAD cells that were untransfected or transfected with a GFP construct ( Table 2) . We conclude that recognition of MHC phosphopeptides endogenously expressed on cancer cells by specific CD8 ϩ T lymphocytes is a direct result of both the level of expression and phosphorylation of the underlying source protein. Collectively, these results provide important validation of these peptides as potential targets for cancer immunotherapy.
Methodologies used to discover class I MHC-restricted antigens displayed selectively on cancer cells frequently involve identification of the peptide target recognized by an already characterized T lymphocyte (30) . Another approach relies on the ability to identify candidate source proteins, usually based on selective expression or overexpression and on the use of predictive algorithms to identify appropriate peptide sequences. Here, we employ a combination of isotopic labeling, enrichment of phosphopeptides by immobilized metal-affinity chromatography, and differential display MS to compare and sequence class I phosphopeptides presented by multiple cancer cell lines. The focus on the phosphate modification enables ''sifting'' of the complex mixture of MHC-associated peptides by MS to identify a small number of peptides with high relevance to cellular growth control processes. This modification provides the opportunity to rapidly assess the expression of the epitope and not just the source protein in multiple tumors of the same or different histological types with CD8 ϩ T lymphocytes and phosphopeptide-specific antibodies. Our results using this approach establish a category of shared cancer antigens that are directly related to cellular growth control processes. These shared antigens are likely targets for immunotherapy.
Materials and Methods
Cell Lines and Transfectants. All cell lines were grown at 37°C with 5% CO 2 in growth medium consisting of RPMI medium 1640 supplemented with 10% FCS, 15 mM Hepes, and 2 mM L-glutamine. MC38 murine colorectal adenocarcinoma, COV413 (HLA-A2 ϩ and HLA-B7 ϩ ) ovarian carcinoma (31), and DM331 (HLA-A2 ϩ ) (32) and SLM2 (HLA-A2 ϩ ) melanomas were transfected with a chimeric class I MHC molecule (␣1 and ␣2 domains of HLA-A*0201 plus an ␣3 domain of H-2D d ; AAD) and cultured under selection in growth medium supplemented with 600 g͞ml G418 (GIBCO͞BRL, Carlsbad, CA). An AAD transfectant of the BLCL, C1R, was maintained in growth medium supplemented with 300 g͞ml G418. MC38AAD cells were transiently transfected with 2 or 4 g of phIRS2-GFP (a generous gift from Lothar Vassen, Universitatsklinikum Essen, Essen, Germany) or 2 g pMAXGFP plasmid using Nucleofector kit V (Amaxa Biosystems, Gaithersburg, MD) according to the manufacturer's directions. Cells were used to stimulate CD8 ϩ T lymphocytes 48 h after transfection, as described below.
Antibodies. An antibody specific for pSer 1100 in IRS2 was generated by AnaSpec (San Jose, CA) by immunizing rabbits with a phosphopeptide conjugate of keyhole limpet hemocyanin corresponding to residues 1095-1108 of IRS2 (ARVApSPTSGVKRL). Other antibodies were obtained as follows: ␤-catenin phosphorylated on Ser 33 (catalog no. sc-16743-R; Santa Cruz Biotechnology, Santa Cruz, CA), IRS2 protein (catalog no. 06-506; Upstate Biotechnology, Charlottesville, VA), and ␤-catenin (catalog no. sc-7199, Santa Cruz Biotechnology).
Isolation of HLA-Associated Peptides. Class I MHC molecules were immunoaffinity-purified from the four cell lines, and their associated peptides were extracted as previously described (11) . Cells (2 ϫ 10 9 to 5 ϫ 10 9 ) were lysed in a solution containing 20 mM Tris⅐HCl (pH 8.0), 150 mM NaCl, 1% CHAPS, 1 mM PMSF, 5 g͞ml aprotinin, 10 g͞ml leupeptin, and 10 g͞ml pepstatin A. All protease inhibitors were purchased from Roche Applied Science (Indianapolis, IN). Phosphatase inhibitors (cocktails I and II from Sigma-Aldrich, St. Louis, MO) were added at a dilution of 1:100 to prevent dephosphorylation of peptides during extraction. The mixture was subjected to centrifugation, and the resulting supernatant was passed over an Econocolumn (Bio-Rad, Hercules, CA) containing the HLA-A2-specific Ab, BB7.2, bound to recombinant-protein A fastflow Sepharose beads (Amersham Pharmacia Biotech, Piscataway, NJ) (33) . Peptides were eluted from the purified class I MHC molecules with 0.2 M acetic acid. The concentration of acetic acid in the resulting solution was adjusted to 10%, and peptides were separated from ␤-microglobulin and MHC molecules by filtration through a 5-kDa cutoff (UFC4LCC25) filter (Millipore, Billerica, MA). Extracted peptides were stored at Ϫ80°C.
Liquid Chromatography͞MS (LC͞MS).
HLA-A*0201 peptides extracted from 1 ϫ 10 8 cells were analyzed by nanoflow-HPLC͞ microelectrospray ionization coupled directly to a home-built Fourier-transform ion cyclotron resonance mass spectrometer (34) . Briefly, samples were loaded onto a 7-cm, reversed-phase C 18 ogies, Phoenix, AZ), packed with 5-m, C18 particles (YMC, Milford, MA), and gradient [gradient A: 0.1 M acetic acid (SigmaAldrich) in H 2 O; gradient B: 70% acetonitrile (Mallinckrodt, Phillipsburg, NJ) and 0.1 M acetic acid in H 2 O], eluted (0-60% gradient B in 20 min and 60-100% gradient B in 5 min) through a 2-m diameter, laser-pulled electrospray tip (micropipette puller model P-2000; Sutter Instrument, Novato, CA) directly into the mass spectrometer with an 1100 series binary LC pump (Agilent, Palo Alto, CA) at a flow rate of Ϸ60 nl͞min. Full-scan mass spectra (300 Յ m͞z Յ 2,000) were collected at one scan per second, with a resolution of 5,000-10,000.
Phosphopeptide Enrichment. Immunoaffinity-purified peptides were converted to methyl esters as previously described (35) , except that the reaction was performed twice using anhydrous methanol and acetyl chloride (Alltech Biotechnology, Deerfield, IL). Samples were taken to dryness, reconstituted in 30 . Phosphopeptides were eluted with a 1-h gradient (0-60% gradient B in 60 min and 60-100% gradient B in 3 min) as described above, except that elution was to a hybrid, linear-quadrupole ion-trap͞Fourier-transform massspectrometer (13) (Thermo Electron Corporation, Waltham, MA). The instrument was operated in a data-dependent mode and cycled through acquisition of a full-scan mass spectrum with the Fourier-transform mass spectrometer plus 10 MS͞MS spectra recorded in the linear trap on the top 10 most abundant ions observed in the full-scan spectrum. Other experimental parameters included (i) one microscan per spectrum, (ii) Ϯ1.5 Da precursor m͞z, (iii) 35% collision energy, (iv) 30-ms ion activation, and (v) 40-s dynamic exclusion.
Comparative Analysis of MHC Phosphopeptides. HLA-A*0201 peptide samples from each of the four different cell lines were divided in half and converted to methyl esters with either d 0 -or d 4 -methanol, as described above (12) . Samples with different isotopic labels from any two of the cell lines were combined, enriched for phosphopeptides by immobilized metal-affinity chromatography, and analyzed by LC͞MS as described above. In these experiments, signals for class I MHC phosphopeptides presented on the surface of both cell lines appear in the mass spectrum as doublets separated by 3 m͞z units per carboxylate group in the molecule. Phosphopeptides that are unique to one or the other cell line appear as singlets. Data analysis was performed by using a three-dimensional visual representation of the chromatogram available in the Xcalibur software (Thermo Electron Corporation). Peptide sequences were determined by a combination of manual interpretation of MS͞MS spectra, accurate mass measurements, and MASCOT Sequence Query (www. matrixscience.com͞home.html). Sequences were confirmed by recording MS͞MS spectra on the corresponding synthetic peptides. Synthetic peptides were prepared by standard Fmoc chemistry using a peptide synthesizer (model APEX 396; Advanced Automated Peptide Protein Technologies, Louisville, KY). Protein sources for confirmed peptide sequences were obtained by searching the nr and refseq databases for human proteins (www.ncbi.nlm.nih.gov͞BLAST).
Western Blot Analysis. Cell pellets were solubilized in lysis buffer (2 ϫ 10 7 cells per milliliter) containing 50 mM Tris⅐HCl, pH 7.4, 1% IGEPAL (Sigma-Aldrich), 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM PMSF, 1 g͞ml aprotinin, 1 g͞ml leupeptin, 1 g͞ml pepstatin A, and 1:100 dilutions of phosphatase inhibitor cocktails I and II. Lysates were centrifuged at 10,000 ϫ g for 30 min at 4°C, and the total amount of protein was determined by using a D C protein assay (Bio-Rad). Samples were boiled in sample buffer for 5 min, and a total of 60 g of protein was loaded and separated on a 4-20% gradient gel (ISC BioExpress, Kaysville, UT) by SDS͞PAGE. Proteins were transferred to Nitropure nitrocellulose (Osmonics, Minnetonka, MN) and blocked with TBS containing 3% nonfat dry milk. Blots were probed overnight with phosphospecific antibodies, washed with TBS containing 0.1% Tween 20, probed with Goat anti-rabbit IgG horseradish peroxidase (Upstate Biotechnology) and developed by using enhanced chemiluminescence (ECL; Amersham Pharmacia). Blots were treated with Restore Western blot stripping buffer (Pierce) for 45 min at 37°C, checked for remaining primary antibody via incubation with goat anti-rabbit IgG horseradish peroxidase, and, if clear, reprobed with antibody to parent protein overnight at 4°C. Blots were then washed and probed with goat anti-rabbit IgG horseradish peroxidase and developed with ECL.
Generation of Phosphopeptide-Specific CD8 ؉ T Lymphocytes and Analysis of Cytokine Production After Stimulation with Cancer Cell
Lines. CD8 ϩ T lymphocytes specific for the indicated phosphopeptides were generated as described previously (11) . Briefly, AAD-transgenic mice were immunized with phosphopeptide-pulsed, activated bone-marrow-derived dendritic cells (11) . Separate bulk splenic T cell cultures were established in vitro with irradiated splenocytes that had been pulsed with the respective phosphorylated peptide at 1 M. Cultures were restimulated with irradiated, phosphopeptide-pulsed splenocytes every 7-10 d in the presence of 10 Cetus units͞ml IL-2 (Chiron, Emeryville, CA). To detect phosphopeptide-specific T cell reactivity, 50,000 CD8 ϩ T lymphocytes were incubated with either 20,000 cancer cells or 20,000 C1RAAD antigenpresenting cells that had been pulsed with different doses of either phosphorylated or nonphosphorylated peptides for 1 h and then washed to remove free peptide. Supernatants were harvested after 24 h and analyzed by ELISA (eBioscience, San Diego, CA) according to the manufacturer's directions for murine IFN-␥ produced by the activated CD8 ϩ T lymphocytes. 
